Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × oblimersen × Dermatologic × Clear all

Phase

Phase 3 2 Phase 2 2 Phase NA 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 2 Lymphoid 2 Tumor-Agnostic 1 Thoracic 1 Other hematologic neoplasm 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 85 Cyclophosphamide 59 Nivolumab 58 Ipilimumab 56 fludarabine 28 aldesleukin 24 Interleukin-2 23 Vemurafenib 22 fludarabine phosphate 21 trametinib 19 Biopsy 19 dabrafenib 14 Radiotherapy 14 Magnetic Resonance Spectroscopy 14 Filgrastim 14 Cisplatin 14 Temozolomide 13 Specimen Handling 12 Gemcitabine 12 atezolizumab 11 Carboplatin 11 romidepsin 10 poly ICLC 10 Peripheral Blood Stem Cell Transplantation 10 Paclitaxel 10 Introns 10 Etoposide 10 CTLA-4 Antigen 10 spartalizumab 9 Radiosurgery 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00409383 2011-11-07

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Genta Incorporated

Phase 1 Unknown

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡